Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade A 28.52 1.28% 0.36
ARWR closed up 1.28 percent on Wednesday, July 17, 2019, on 42 percent of normal volume.

Earnings due: Aug 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ARWR trend table...

Date Alert Name Type % Chg
Doji - Bearish? Reversal 0.00%
BB Squeeze Ended Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Bollinger Band Squeeze Range Contraction 1.28%
Up 3 Days in a Row Strength 1.28%
20 DMA Support Bullish 2.59%
Bollinger Band Squeeze Range Contraction 2.59%
Crossed Above 20 DMA Bullish 5.05%
1,2,3 Pullback Bullish Bullish Swing Setup 5.05%

Older signals for ARWR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Infection Molecular Biology Obesity Genetics Gene Expression Hepatitis B RNA Molecular Genetics Apoptosis Chronic Hepatitis B Virus
Is ARWR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 28.84
52 Week Low 10.41
Average Volume 1,983,221
200-Day Moving Average 17.9652
50-Day Moving Average 24.7468
20-Day Moving Average 27.2325
10-Day Moving Average 27.085
Average True Range 0.9765
ADX 35.43
+DI 30.6881
-DI 12.2413
Chandelier Exit (Long, 3 ATRs ) 25.9105
Chandelier Exit (Short, 3 ATRs ) 28.6095
Upper Bollinger Band 28.7581
Lower Bollinger Band 25.7069
Percent B (%b) 0.92
BandWidth 11.20426
MACD Line 0.7074
MACD Signal Line 0.736
MACD Histogram -0.0285
Fundamentals Value
Market Cap 2.13 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -44.56
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.72
Resistance 3 (R3) 29.66 29.20 29.52
Resistance 2 (R2) 29.20 28.89 29.23 29.45
Resistance 1 (R1) 28.86 28.71 29.03 28.92 29.39
Pivot Point 28.40 28.40 28.49 28.43 28.40
Support 1 (S1) 28.06 28.09 28.23 28.12 27.65
Support 2 (S2) 27.60 27.91 27.63 27.59
Support 3 (S3) 27.26 27.60 27.52
Support 4 (S4) 27.32